Module 21
EU GMP Annex 13 and Investigational Medicinal Product Manufacture
Course Overview
This course provides the comprehensive understanding needed by professionals manufacturing, testing, releasing, supplying or regulating Investigational Medicinal Products for use in clinical trials. It addresses the distinct GMP framework that governs IMP manufacture under EU GMP Annex 13 and the wider Clinical Trial Regulation, and the operational realities of an environment where the product is still in development, the manufacturing process may be evolving, and the QP carries certification accountability against a less mature evidence base than commercial product certification involves.
IMP manufacture sits at the intersection of clinical research and pharmaceutical manufacturing, and the discipline reflects both contexts. The regulatory framework is built around the principle that trial subjects deserve the same quality protection that authorised medicinal product patients receive, but it accommodates the reality that the product is in development. Specifications may be provisional. Manufacturing processes may be at small scale or in non-routine equipment. Blinding requirements introduce documentation and labelling complexity that does not exist for commercial product. Comparator products may need to be re-packaged. Placebos may need to be manufactured to match active product. Supply quantities may be small, geography may be widely distributed across trial sites, and the manufacturing process may change during the clinical programme as development progresses.
This course addresses the operational reality of IMP manufacture: the EU Clinical Trial Regulation framework and the role of national authorities, the IMP Dossier and Investigational Medicinal Product Dossier requirements, the QP certification framework under Annex 13 including the specific differences from Annex 16 commercial product certification, the manufacture and management of comparator products and placebos, the controls for blinding and randomisation, the import requirements for IMPs manufactured outside the EU and used in EU clinical trials, the management of returns and reconciliation, and the inspection expectations that apply to IMP manufacturing operations.
The course is designed for professionals working in clinical supply organisations, contract manufacturers offering IMP services, sponsor companies managing in-house or outsourced IMP supply, and CDMOs whose service mix includes IMP manufacture alongside commercial product activities.
Learning Outcomes
By the end of this course, learners will be able to:
- Explain the regulatory basis for IMP manufacture under EU GMP Annex 13, the EU Clinical Trial Regulation (Regulation 536/2014) and the supporting framework of guidelines and Commission Delegated Regulation 2017/1569.
- Describe the IMP Dossier requirements and how the manufacturing, quality and stability information is structured to support the clinical trial application.
- Explain the role of the QP in IMP certification, including the specific Annex 13 expectations that differ from Annex 16 commercial product certification, and the additional considerations that apply when certifying IMPs.
- Distinguish between IMPs, auxiliary medicinal products, comparator products and placebos, and apply the appropriate GMP framework to each category.
- Apply IMP-specific manufacturing controls including blinding and randomisation management, code break procedures, the preparation of placebos to match active product and the management of comparator product re-packaging.
- Explain the labelling requirements for IMPs including the regulatory information required, language requirements for multi-country trials, and the labelling adaptations required when blinding must be preserved.
- Describe the importation requirements for IMPs manufactured outside the EU and used in EU clinical trials, including the role of the QP for importation and the specific evidence required to support importation certification.
- Apply Annex 13 expectations to facility design, equipment qualification, process validation considerations for evolving processes, analytical method validation for products under development and supplier qualification for IMP-specific materials.
- Recognise the principles of IMP supply management including order management, distribution to trial sites, temperature management during shipment, returns reconciliation and IMP destruction.
- Identify situations requiring escalation, including manufacturing deviations affecting IMP supply, labelling errors, blinding compromises, code break events, stability concerns affecting trial continuation and import or export issues affecting trial site supply.
- Explain how IMP manufacture differs operationally from commercial product manufacture and how a manufacturing organisation can manage both activities without compromising either.
Course Content
Clinical trial activity is one of the most active areas of pharmaceutical operations. The development pipeline across the industry contains many thousands of active clinical programmes at any time, and the IMP supply requirements that support those programmes represent a substantial proportion of CDMO and clinical supply organisation revenue. Every new pharmaceutical product passes through clinical development before commercial approval, and the IMP framework governs how the medicinal product is manufactured, tested, released and supplied during that period.
The regulatory framework for IMPs was substantially updated by the EU Clinical Trial Regulation, which became applicable in January 2022, and the supporting GMP framework under Annex 13 and Commission Delegated Regulation 2017/1569. The framework provides specific expectations for IMP manufacture that differ in material ways from commercial product GMP. Process validation expectations are calibrated for a product whose manufacturing process may be at early or evolving development stage. Specification expectations recognise that the product’s analytical profile is still being established. Stability data may be limited at the start of a clinical programme and may be extended through ongoing study during the trial. QP certification under Annex 13 carries the same accountability as commercial certification but operates against a less mature evidence base.
The blinding and randomisation requirements introduce a distinctive layer of complexity. IMP manufacture for double-blind studies requires that the appearance, packaging and labelling of active product, placebo and comparator products be indistinguishable to the trial subject, the investigator, and often to the manufacturing and supply chain personnel handling the product. This requires manufacturing controls, labelling controls, code break procedures and supply chain controls that do not exist for commercial product. Errors in blinding can compromise the integrity of the clinical trial and the regulatory submission that depends on it.
Importation considerations are particularly relevant. Many IMPs used in EU clinical trials are manufactured outside the EU. The QP for importation carries responsibility for certifying that imported IMPs meet the EU manufacturing standards and the IMP Dossier requirements. This is a different exercise from certifying a commercial imported product, because the regulatory commitments and evidence base differ. Organisations managing IMP importation regularly need professional development to keep this discipline current.
This course is essential because IMP manufacturing competence is often built through informal experience rather than structured training. The framework’s specific expectations are widely under-appreciated in organisations whose primary focus is commercial product manufacture. Sponsor organisations managing outsourced IMP supply may have limited internal IMP expertise. CDMOs offering IMP services need to maintain the discipline despite the smaller proportion of their revenue that IMP work may represent. QPs certifying IMPs need to understand the specific Annex 13 expectations alongside the Annex 16 commercial product expectations.
The regulatory framework for IMP manufacture
The course opens by establishing the regulatory framework for IMPs. This includes the EU Clinical Trial Regulation 536/2014, Commission Delegated Regulation 2017/1569 setting out the principles and guidelines for GMP for IMPs, the EudraLex Volume 4 Annex 13 framework where applicable and the relationship between the IMP regulatory framework and commercial product GMP under Annex 16.
The IMP Dossier and supporting documentation
A dedicated section addresses the IMP Dossier and the manufacturing, quality and stability information that supports it. Learners will understand how the dossier is structured, what evidence is required, how it evolves as the clinical programme progresses through Phase 1, Phase 2 and Phase 3, and how substantial amendments to the dossier are managed during a trial.
QP certification of IMPs
The course addresses QP certification under Annex 13 in operational depth. Learners will understand the specific Annex 13 certification expectations, how they differ from Annex 16 commercial certification, what evidence the QP must be satisfied with before certifying an IMP batch, and how QPs operate in the IMP context where the manufacturing process may be evolving, specifications may be provisional and stability data may be limited.
Blinding, randomisation and code break procedures
Blinding is addressed as one of the distinguishing features of IMP manufacture. The course covers the principles of manufacturing controls to support blinding, the labelling controls that protect the blind, the code break procedures that must be in place for emergency unblinding, the supply chain controls that protect the blind from inadvertent disclosure and the documentation controls that maintain integrity of the blinding information.
Comparator products and placebos
The manufacture and management of comparator products and placebos is addressed in its own right. This includes the controls for purchasing commercial product for use as comparator, the re-packaging considerations where the comparator must be presented in a blinded format, the requirements for placebo manufacture to match active product in appearance and packaging, and the documentation and traceability expectations across these activities.
IMP labelling
The course addresses IMP labelling requirements including the regulatory information required under the EU framework, the language requirements for multi-country trials, the considerations for emergency code break information on labels, the management of label changes during a trial and the inspection expectations for labelling controls.
Importation of IMPs into the EU
Importation is addressed in detail given its operational importance. Learners will understand the QP for importation role, the evidence required to support certification of imported IMPs, the differences from commercial product importation and the practical management of IMP supply across jurisdictions during multi-country clinical trials.
IMP supply chain management
A dedicated section addresses IMP supply chain management. This includes order management from clinical sites, distribution and temperature management during shipment, returns reconciliation when unused IMP is returned at the end of a trial or by individual subjects, and the destruction of IMP material at trial closure.
Process validation, analytical methods and stability in an IMP context
The course addresses process validation expectations for evolving manufacturing processes, analytical method validation for products under development, and the management of stability data that may be limited at trial initiation and extended through ongoing study. This includes how to set appropriate provisional specifications and how to manage specification changes as the product profile matures.
Cross-functional accountability and inspection readiness
A dedicated section maps Annex 13 expectations to the functions responsible for meeting them, and the final section addresses inspection readiness for IMP manufacturing operations. This includes how inspectors approach IMP facilities, what they typically focus on, what common findings look like and how to prepare an IMP operation for inspection scrutiny.
- Clinical supply professionals working in clinical supply organisations, CDMOs, sponsor companies and academic institutions involved in IMP manufacture and supply.
- Qualified Persons and QPs-in-training responsible for certification of IMPs or developing the IMP certification competence as part of their qualifying experience.
- QA professionals with IMP-specific responsibilities including IMP batch review, dossier management, supplier oversight for IMP-specific materials and inspection readiness for IMP
- Regulatory Affairs professionals managing IMP dossiers, substantial amendments, importation evidence and clinical trial application materials.
- Production and packaging professionals working in IMP-specific facilities or in dual-purpose facilities running both commercial and IMP operations.
- Sponsor organisation clinical operations and clinical supply teams managing in-house or outsourced IMP supply for company-sponsored clinical programmes.
- Distribution, logistics and supply chain teams managing IMP shipment, returns reconciliation and trial site supply.
- Procurement teams responsible for sourcing comparator products, placebo materials and IMP-specific consumables.
- Internal auditors and inspection readiness leads working with IMP
- Senior leaders and executive teams in CDMOs, sponsor companies and clinical supply organisations accountable for IMP capability, capacity and regulatory standing.
You will gain a comprehensive understanding of the regulatory framework that governs IMP manufacture and the operational discipline required to deliver IMP supply to clinical trials at the standard the framework demands. You will be able to interpret Annex 13 and the wider IMP framework with precision, recognise where IMP GMP diverges from commercial GMP and apply the right expectations to the right activity.
For those in IMP manufacturing, certification or quality roles, this course builds the regulatory authority needed to defend operational decisions to inspectors, sponsors and corporate leadership. For QPs handling both Annex 16 commercial product and Annex 13 IMP certifications, the course clarifies the framework differences and supports defensible certification decisions across both contexts.
Organisations benefit from a workforce that understands IMP manufacture as the distinct discipline it is. This strengthens clinical supply quality, improves IMP dossier quality, supports more reliable QP certification decisions and reduces the risk of trial disruption arising from IMP quality or supply failures.
For CDMOs and clinical supply organisations, the course supports stronger commercial credibility with sponsor clients and stronger inspection readiness for IMP-specific scrutiny. For sponsor organisations, it supports more capable in-house IMP oversight and more confident management of outsourced IMP arrangements.
Clinical trial disruption arising from IMP quality or supply failure is one of the most expensive outcomes in pharmaceutical development. The cost of building genuine IMP competence is reliably lower than the cost of managing its absence.
- Comprehensive expert video content covering EU GMP Annex 13, the Clinical Trial Regulation 536/2014, Commission Delegated Regulation 2017/1569 and IMP-specific quality system
- Real-world case studies from clinical supply, IMP-specific CDMO operations, sponsor-managed IMP supply and IMP inspection environments.
- Practical examples of IMP Dossier construction, QP certification under Annex 13, blinding and code break management, comparator and placebo manufacture and IMP importation.
- Cross-functional scenarios showing how production, QA, regulatory affairs, clinical operations, supply chain and senior leadership affect IMP compliance and trial continuity.
- Exercises on blinding integrity assessment, IMP labelling decision-making, comparator procurement and substantial amendment management.
- Inspection-readiness scenarios focused on defending IMP manufacturing and certification
- Multi-choice assessment
- Certificate of completion upon passing the
Course Details
Instructor(s):
Paul Palmer & Aneta Jell
Level:
Mastery
Duration:
3.5 Hours
Type:
Instructor led
Launch Yourself Into The Future.
Join Academy Pharmaceutical Excellence to gain industry-leading knowledge and skills through our comprehensive courses designed for aspiring professionals.